Indications for urokinase

　　This product is mainly used for thrombolytic treatment of thromboembolic diseases. These included acute generalized pulmonary embolism, coronary artery embolization and myocardial infarction within 6-12 hours of chest pain, acute cerebrovascular embolization with symptoms shorter than 3-6 hours, retinal artery embolization, and other severe ilio-femoral vein thrombosis with peripheral artery embolization symptoms. It is also used to prevent thrombosis after artificial heart flap operation and to maintain the patency of vascular intubation, thoracic cavity and pericardial cavity drainage tube. The efficacy of thrombolytic therapy should be maintained by subsequent heparin anticoagulation.

　　This product is an enzymatic thrombolytic agent, which can activate in vivo plasminogen into plasminogen, thereby hydrolyzing fibrin to dissolve freshly formed thrombi. For acute myocardial infarction, acute cerebral thrombosis and cerebral vascular embolism, peripheral arteriovenous thrombosis, central retinal arteriovenous thrombosis and other fresh thromboocclusive diseases. This product has no obvious effect on old thrombosis. It is also applicable to the treatment of cerebral thrombosis, peripheral vascular embolization, central retinal vascular embolization, acute myocardial infarction and other new thromboembolic diseases, as well as renal transplantation, orthopedic surgery and other thrombosis, with good efficacy.